Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.46 |
| ▸ | TFPI | P10646 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.42 |
| ▸ | CALCR | P30988 | 2/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628789 | 0.90 | KEAP1 (0.52) | APLNRKEAP1NMUR2NMUR1 | |
| SCHEMBL30065432 | 0.87 | APLNR (0.49) | IL23RTFPIOPRM1OPRK1APLNR | |
| Adamantane SCHEMBL5324119 | 0.84 | RAMP3 (0.49) | EPHA2OPRM1NMUR2NMUR1CXCR4 | |
| SCHEMBL30887071 | 0.84 | CXCR4 (0.46) | IL23REPHA2KEAP1CXCR4RAMP3 | |
| SCHEMBL29440833 | 0.83 | OPRM1 (0.54) | TFPIOPRM1OPRK1APLNRRAMP3 | |
| SCHEMBL5066529 | 0.82 | EPHA2 (0.47) | EPHA2TFPIOPRM1OPRK1CALCRL | |
| SCHEMBL9293165 | 0.82 | NMUR2 (0.51) | KEAP1NMUR2NMUR1CXCR4RAMP3 | |
| SCHEMBL9293866 | 0.82 | NMUR2 (0.50) | EPHA2OPRM1NMUR2NMUR1CXCR4 | |
| SCHEMBL30887066 | 0.82 | CXCR4 (0.45) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL30887061 | 0.81 | CXCR4 (0.41) | EPHA2OPRM1KEAP1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228665-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-20240076408-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-03-07 | — | — | US | disclosed |
| US-20240067751-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | KEYMED BIOSCIENCES CO.,LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11884742-B2 | Methods for treating conditions associated with MASP-2 dependent complement activation | OMEROS CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230391889-A1 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | OMEROS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| EP-4265641-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | Keymed Biosciences Co.,Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022127834-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | 康诺亚生物医药科技（成都）有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114634575-A | Development and application of complement inhibitor | 康诺亚生物医药科技（成都）有限公司 | 2022-06-17 | — | — | CN | disclosed |